The Methodist Hospital Research Institute

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, The Methodist Hospital Research Institute sits in the top decile of US sponsors by registered trial count (#214 of 15,742 sponsors by registered trial count).

126 total trials 49 currently recruiting 48 completed early-phase tilt top decile by trial count

The Methodist Hospital Research Institute: 126 sponsored US clinical trials, 49 recruiting.

The Methodist Hospital Research Institute sponsors 126 registered US clinical trials on ClinicalTrials.gov, 49 of them currently recruiting, and 48 completed. 12 of these trials are in Phase 3-4 (later-stage) and 65 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urge Incontinence, with 2 trials.

Top-decile sponsor footprint

The Methodist Hospital Research Institute ranks in the top decile of sponsors by registered trial count (#214 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 27/100

48 of 64 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

126 total, page 3 of 3

COMPLETED

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

NCT03033355

COMPLETED Phase 2

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

NCT02073487

TERMINATED Phase 1

A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy

NCT02111824

COMPLETED Phase 2

Olive Oil for High Risk Breast Cancer Prevention in Women

NCT02068092

COMPLETED Phase 3

Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation

NCT01898221

COMPLETED Phase 4

Ciprofloxacin for Prevention of BK Infection

NCT01789203

TERMINATED NA

The Use of CoSeal (Sealant Agent) in Patients During Left Ventricular Assist Device Surgery

NCT01605019

COMPLETED Phase 2

Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)

NCT01446016

COMPLETED Phase 2

A Trial of Esophageal and Gastric Stenting for Leak or Perforation

NCT01107249

COMPLETED

Safety of Riluzole in Patients With Acute Spinal Cord Injury

NCT00876889

COMPLETED Phase 2

Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

NCT01097642

COMPLETED

Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis

NCT01592084

TERMINATED Phase 2

Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer

NCT00521274

TERMINATED Phase 2

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

NCT00521781

TERMINATED Phase 4

Adrenal Insufficiency in Septic Shock

NCT00842933

TERMINATED Phase 1

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

NCT00522249

TERMINATED Phase 2

Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

NCT00448097

COMPLETED Phase 1

Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer

NCT00448149

TERMINATED Phase 2

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

NCT00450008

TERMINATED Phase 2

Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

NCT00440973

TERMINATED Phase 2

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

NCT00447473

COMPLETED Phase 2

Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

NCT00445523

COMPLETED Phase 2

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

NCT00448409

COMPLETED Phase 2

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

NCT00445042

COMPLETED Phase 2

Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer

NCT00446368

COMPLETED Phase 2

Efficacy and Safety Study of Xyotax to Treat Prostate Cancer

NCT00446836

← Previous Page 3 of 3

What is open in the The Methodist Hospital Research Institute pipeline

49 recruiting of 126 indexed (39% open); 48 completed (38%).

Phase mix: 12 late (III/IV) vs 65 early (I/II) (early-phase heavy).

Top condition: Urge Incontinence (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

The Methodist Hospital Research Institute: open-pipeline peers nationwide

Peers matched on 126 registered trials and 39% open enrollment, not the therapeutic-area sidebar.

The Methodist Hospital Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150 10%20%30%40%50% Total trials Recruiting share The Methodist Hospital Research InstituteStony Brook UniversityMethodist Health SystemJazz PharmaceuticalsUniversity of Illinois at Urbana-ChampaignargenxMorehouse School of MedicineNortheastern UniversityThomas Hope
The Methodist Hospital Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

The Methodist Hospital Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 126 trials (± recruiting share)

Sponsors near 39% open enrollment (± trial volume)

What to do with this The Methodist Hospital Research Institute page

126 registered trials is a research-attention snapshot, not an endorsement of The Methodist Hospital Research Institute or any single study.

  • 49 of The Methodist Hospital Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Urge Incontinence is the condition The Methodist Hospital Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urge Incontinence trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

The Methodist Hospital Research Institute pipeline card: 126 registered trials from official public datasets.Report a data error.